Colchicine News and Research

RSS

Hepatitis C therapy peginterferon alfa-2b shows promise

The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).

24 Apr 2008

FDA to stop the marketing of unapproved injectable colchicine

The U.S. Food and Drug Administration has announced its intention to take enforcement action against companies marketing unapproved injectable colchicine, a drug used to treat gout.

7 Feb 2008

Novel cellular mechanism that may guide cell movement and possibly cancer cell invasion

Scientists have long thought that microtubules, part of the microscopic scaffolding that the cell uses to move things around in order to hold its shape and divide, originated from a tiny structure near the nucleus, called the centrosome.

23 Jun 2007

Colchicine delays development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis

Colchicine, an anti-inflammatory drug most often used to treat gout, prevented liver cancer in patients with hepatitis virus-related end-stage liver disease, according to a new study.

11 Sep 2006

Patients with primary biliary cirrhosis who are treated with methotrexate have an increased risk of death

In five randomized controlled trials involving 457 people, the authors report that for patients treated with methotrexate, as a single therapy or in combination with other drug treatment, pooled data showed a tendency toward an increased risk of death or liver transplantation. The brand names for methotrexate are Rheumatrex and Trexall.

23 Aug 2005

New approaches for the treatment of chronic hepatitis C

Data from two ongoing studies testing new approaches for the treatment of chronic hepatitis C was presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) this afternoon.

1 Nov 2004